Wednesday, July 8, 2026

pharma · RSV Infection · NASH - Nonalcoholic Steatohepatitis · ENTA

ENANTA PHARMACEUTICALS

Enanta Pharmaceuticals is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker ENTA. Primary therapeutic focus areas include RSV Infection, NASH - Nonalcoholic Steatohepatitis, Non-Alcoho

4 Kingsbury Ave, Watertown, Massachusetts 02472, US HQ
1995 Founded
145 Employees
Public company Type
ENTA · NYSE Ticker
Company details
Status
Public
HQ
4 Kingsbury Ave, Watertown, Massachusetts 02472, US
Founded
1995
Employees
145
Programs
34
Drugs
15
Patents
218
Clinical program

EDP-305 1.5 mg

Phase 2 · small molecule · Non-Alcoholic Steatohepatitis

EDP-305 1.5 mg for Non-Alcoholic Steatohepatitis is a Phase 2 program (small_molecule) at ENANTA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

← All ENANTA PHARMACEUTICALS INC projects Phase 2 small molecule terminated

Internal code EDP 305-102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ENANTA PHARMACEUTICALS INC
Phase
Phase 2
Modality
small_molecule
Indication
Non-Alcoholic Steatohepatitis
Status
terminated
Trials
1